Move Over Late-Stage Alliances; Enter Acquisitions

The higher the cost of late-stage alliances, the likelier acquisitions are. And that's just what our statistical view of significant acquisitions is showing--the number of $100mm-plus biotech acquisitions has increased dramatically over the last half-decade, including an increasing percentage from Big Pharma.

The higher the cost of late-stage alliances, the likelier acquisitions are.

And that's just what our view of significant acquisitions is showing—including an increasing percentage from Big Pharma. From 1996-2000, Big...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from In Vivo